IVIG Treatment for Asthmatic Patients With IgG Subclass Deficiency

• Status: Unknown status
• Trial end date: 2017-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Immunoglobulin G deficiency subtypes in patients with asthma six months once a month intravenous immunoglobulin (400mg/kg/4weeks) infection in treatment-related effect on reducing the frequency of asthma exacerbations appreciate.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ajou University School of Medicine
• Treatments: Antibodies; gamma-Globulins; Immunoglobulin G; Immunoglobulins; Immunoglobulins, Intravenous; Rho(D) Immune Globulin

Criteria

Inclusion Criteria:

• The patient from over 16 years to under 75 years

• Patients diagnosed with asthma over six months ago

• immunoglobulin G subtypes who were diagnosed with immune deficiency

• more than 2 years Upper and lower respiratory tract infections

, and asthma exacerbations in this regard.

• ① calculated creatinine clearance ≧ 50ml/min

• ALT and AST- ALP

• total bilirubin

Exclusion Criteria:

• within six months of the onset of the experiment who received immunoglobulin therapy

• immune globulin for those with a history of hypersensitivity reactions

• six months ago, another clinical trial participants.

• Systemic steroids and immunomodulators, such as asthma control that may affect the resources required drug administration.

• pregnant or lactating women.